Viracta Therapeutics, Inc. Common Stock

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' expectations. Core income per share reached $4.69 from $4.11 a year ago, missing the $4.90 consensus forecast. Net income per share rose to $4.80 from $4.13 a year earlier. Travelers shares dipped 8.1% to $205.03 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers INVO Bioscience, Inc. (NASDAQ: INVO) shares shot up 256% to $2.78 after the company reported a year-over-year increase in fourth-quarter revenue results and said it remains on track to reach its goal of reaching break-even or profitability within its current operations in 2024. Edible Garden AG Incorporated (NASDAQ: EDBL) gained 112% to $9.73 after the company reported preliminary first quarter FY24 results. Sintx Technologies, Inc. (NASDAQ: SINT) jumped 53% to $0.0350. VIA optronics AG (NYSE: VIAO) shares gained 50.4% to $0.3924 after dipping over 15% on Tuesday. AERWINS Technologies Inc. (NASDAQ: AWIN) jumped 42.2% to $4.70. The Children's Place, Inc. (NASDAQ: PLCE) climbed 35.5% to $9.64 after the company announced it entered into a new financing agreement with Mithaq Capital. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) gained 32% to $5.38 after the company announced that it submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda Pharmaceuticals and confirmed that its most recent proposal to acquire Vanda remains open for Vanda and its Board of Directors to consider. EZGO Technologies Ltd. (NASDAQ: EZGO) gained 28% to $2.20. EZGO entered into a strategic cooperation framework agreement with Woteam to jointly explore the Southeast Asian Market. CXApp Inc. (NASDAQ: CXAI) shares rose 25% to $4.89 after the company announced 24% ARR growth in 2023. TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) rose 19.6% to $2.0461. WiSA Technologies, Inc. (NASDAQ:

Related tickers: DXYZ, SBFM, OTRK, AMC, ALXO, ADPT, VIAO, ADSK, SAGE, EZGO, ASML, TCON, ISUN, DYNT, FWRD, CHRO, LGVN, IBKR, TPET, VIRX, JBHT, TMQ, FNCH, MSTR, PRTG, RANI, PLCE, CGEM, HUBC, SPEC, WISA, EDBL, VNDA, SXTC, DFLI, ARM, SINT, AWIN, MEG, SMXT, CXAI, TRV, SNDL, IZM, VFS, UAL, INVO.

The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy [n=10] or to nanatinostat in combination with valganciclovir [Nana-val, n=10]), with an aim to clearly delineate the differentiation of Nana-val’s ‘Kick and Kill’ mechanism of action The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy [n=10] or to nanatinostat in combination with valganciclovir [Nana-val, n=10]), with an aim to clearly delineate the differentiation of Nana-val’s ‘Kick and Kill’ mechanism of action

Related tickers: VIRX.